Jane Street’s Fulcrum Therapeutics FULC Stock Holding History

Jane Street’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,500	Closed	-$129K	–	9792
2024 Q4	$129K	Sell	27,500 -50,600	-65%	-$187K	﹤0.01%	8647
2024 Q3	$279K	Buy	+78,100	New	+$579K	﹤0.01%	8150
2023 Q2	–	Sell	-12,500	Closed	-$35.6K	–	8961
2023 Q1	$35.6K	Buy	+12,500	New	+$112K	﹤0.01%	8535
2022 Q1	–	Sell	-17,500	Closed	-$310K	–	10529
2021 Q4	$310K	Buy	17,500 +8,000	+84%	+$158K	﹤0.01%	8106
2021 Q3	$268K	Buy	+9,500	New	+$180K	﹤0.01%	8401

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jane Street's FULC Position: Q1 2026 in Review

Jane Street reduced its Fulcrum Therapeutics (FULC) stake by 37% in Q1 2026, selling an estimated $1.7M and leaving 310,417 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Jane Street first reported a position in FULC in Q3 2021 and has held it in 18 quarters since. The position peaked at $5.58M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Jane Street held 310,417 shares of Fulcrum Therapeutics worth $2.38M as of Q1 2026.
Jane Street sold 183,333 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.7M.
Fulcrum Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4750 holding.
Jane Street first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 18 quarters since.
Jane Street's Fulcrum Therapeutics position peaked at $5.58M in Q4 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.